Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy

HIV Clinical Trials

Volumn 13, Issue 4, 2012, Pages 212-221

  Ross, Allison ^a   Hileman, Corrilynn ^b   Brown, Todd ^c   Fedarko, Neal ^c   Storer, Norma ^b   Labbato, Danielle ^b   McComsey, Grace ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

bone mineral density; bone turnover markers; HIV; rosiglitazone; thiazoledinediones

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; CYTOKINE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; PROCOLLAGEN TYPE 1 AMINOTERMINAL PROPEPTIDE; PROTEINASE INHIBITOR; ROSIGLITAZONE; TENOFOVIR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY FAT; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; BONE AND BONES; BONE DENSITY; COLLAGEN TYPE I; DIABETES MELLITUS, LIPOATROPHIC; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOCALCIN; PEPTIDES; THIAZOLIDINEDIONES;

EID: 84864689257     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1304-212     Document Type: Article

References (58)

1. Brown TT, Qaqish RB. Antiretroviral therapy and the preva-lence of osteopenia and osteoporosis: a meta-analytic review see comment. AIDS. 2006;20(17):2165-2174.
2. Dao C, Young B, Buchacz K, Baker R, Brooks J; HOPS. Higher and increasing rates of fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared to the general US population, 1994 to 2008. Paper presented at: 17th Conference on Retroviruses and Opportunistic Infection; 2010; San Francisco, CA.
3. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture preva-lence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metabol. 2008;93(9):3499-3504.
4. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;27(7):817-824.
5. Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normali-zation of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metabol. 1999;84(1): 145-150.
6. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36(4):482-490.
7. Moore AL, Vashisht A, Sabin CA, et al. Reduced bone mineral density in HIV-positive individuals. AIDS. 2001;15(13):1731-1733.
8. Fausto A, Bongiovanni M, Cicconi P, et al. Potential predic-tive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38(6):893-897.
9. Bongiovanni M, Fausto A, Cicconi P, et al. Osteoporosis in HIV-infected subjects: a combined effect of highly active antiretroviral therapy and HIV itself? J Acquir Immune Defic Syndr. 2005;40(4):503-504.
10. McComsey GA, Kitch D, Daar ES, et al. Bone mineral den-sity and fractures in antiretroviral-naive persons random-ized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791-1801.
11. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004;15(1):49-60.
12. Aukrust P, Muller F, Lien E, et al. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis. 1999;179(1): 74-82.
13. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51(5): 554-561.
14. Moyle G, Givens N, Pearce H, Compston J; ASSERT. Effect of ART on bone turnover markers and bone den-sity in HIV infected patients. Paper presented at: 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV; 2009; Philadelphia, PA.
15. Fakruddin JM, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol. 2005;150(1):67-78.
16. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem. 2003;278(48):48251-48258.
17. Seminari E, Castagna A, Soldarini A, et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med. 2005;6(3):145-150.
18. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS. 2001;15(14):1823-1829.
19. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354(9184):1112-1115.
20. Mallon PW, Sedwell R, Rogers G, et al. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis. 2008;198(12):1794-1803.
21. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106-1118.
22. Tungsiripat M, Bejjani DE, Rizk N, et al. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS. 2010;24(9):1291-1298.
23. Raboud JM, Diong C, Carr A, et al. A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials. 2010;11(1):39-50.
24. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005;146(3):1226-1235.
25. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective per-oxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002;143(6):2376-2384.
26. Tornvig L, Mosekilde LI, Justesen J, Falk E, Kassem M. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int. 2001;69(1):46-50.
27. Murphy CE, Rodgers PT. Effects of thiazolidinedio-nes on bone loss and fracture. Ann Pharmacother. 2007;41(12):2014-2018.
28. Douglas IJ, Evans SJ, Pocock S, Smeeth L. The risk of frac-tures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med. 2009;6(9):e1000154.
29. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidin-edione use and bone loss in older diabetic adults. J Clin Endocrinol Metabol. 2006;91(9):3349-3354.
30. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168(8):820-825.
31. Ryan KE, McCance DR, Powell L, McMahon R, Trimble ER. Fenofibrate and pioglitazone improve endothelial func-tion and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis. 2007;194(2):e123-130.
32. Koufany M, Moulin D, Bianchi A, et al. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis. Arthritis Res Ther. 2008;10(1):R6.
33. Hassumi MY, Silva-Filho VJ, Campos-Junior JC, et al. PPAR-gamma agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis. Int Immunopharmacol. 2009;9(10):1150-1158.
34. Jiang M, Lu S, Wu L, Liu J, Cheng P, Ding GX. Effect of pioglitazone on receptor activator of nuclear factor-kappa B expression in osteoclast from RAW264.7 cells. Zhong-hua Yi Xue Za Zhi. 2010;90(32):2282-2285.
35. An JJ, Han DH, Kim DM, et al. Expression and regula-tion of osteoprotegerin in adipose tissue. Yonsei Med J. 2007;48(5):765-772.
36. Schwab AM, Granholm S, Persson E, Wilkes B, Lerner UH, Conaway HH. Stimulation of resorption in cultured mouse calvarial bones by thiazolidinediones. Endocrinology. 2005;146(10):4349-4361.
37. Yarasheski KE, Cade WT, Overton ET, et al. Exercise train-ing augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. Am J Physiol Endocrinol Metabol. 2011;300(1):E243-251.
38. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabe-tologia. 1985;28(7):412-419.
39. Tungsiripat M, El-Bejjani D, Rizk N, et al. Carotid intima media thickness, inflammatory markers, and endothe-lial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo. AIDS Res Human Retroviruses. 2011;27(3): 295-302.
40. Grey A, Bolland M, Gamble G, et al. The peroxisome pro-liferator- activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metabol. 2007;92(4):1305-1310.
41. Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care. 2007;30(6):1574-1576.
42. Eastell R, Hannon RA. Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc. 2008;67(2):157-162.
43. Kushida K, Takahashi M, Kawana K, Inoue T. Comparison of markers for bone formation and resorption in premeno-pausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metabol. 1995;80(8):2447-2450.
44. Seibel MJ, Gartenberg F, Silverberg SJ, Ratcliffe A, Robins SP, Bilezikian JP. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J Clin Endocrinol Metabol. 1992;74(3):481-486.
45. Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005;20(1):141-151.
46. McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007;21(18):2473-2482.
47. Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Ann Clin Biochem. 2000;37(pt 4):432-446.
48. Linkhart SG, Linkhart TA, Taylor AK, Wergedal JE, Bet-tica P, Baylink DJ. Synthetic peptide-based immunoas-say for amino-terminal propeptide of type I procollagen: application for evaluation of bone formation. Clin Chem. 1993;39(11 pt 1):2254-2258.
49. Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international refer-ence standards. Osteoporosis Int. 2011;22(2):391-420.
50. Berberoglu Z, Gursoy A, Bayraktar N, Yazici AC, Bascil Tutuncu N, Guvener Demirag N. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in post-menopausal diabetic women. J Clin Endocrinol Metabol. 2007;92(9):3523-3530.
51. Cummings SR, Black DM, Nevitt MC, et al. Bone den-sity at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993;341(8837):72-75.
52. Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporosis Int. 2002;13(2):105-112.
53. McComsey G, Kitch D, Daar E, et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase iii trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. Paper presented at: 17th Conference on retroviruses and Opportunistic Infections; 2010; San Francisco, CA.
54. Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med. 2009;122(7): 599-604.
55. Sambrook P. Tumour necrosis factor blockade and the risk of osteoporosis: back to the future. Arthritis Res Ther. 2007;9(4):107.
56. Ross AC, Armentrout R, O'Riordan MA, et al. Endothelial activation markers are linked to HIV status and are inde-pendent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr. 2008;49:499-506.
57. Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2009;49(7):1119-1127.
58. Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metabol. 2010;12(8):716-721.